<DOC>
	<DOCNO>NCT02695641</DOCNO>
	<brief_summary>The primary purpose pilot study assess pharmacokinetic profile low-dose bevacizumab effectiveness reduce plasma free VEGF-A level safely hemodialysis patient . This information use plan phase 1 clinical trial evaluate bevacizumab 's role hemodialysis vascular access failure .</brief_summary>
	<brief_title>Reduction Plasma Free VEGF-A Using Low-dose Bevacizumab Hemodialysis Patients</brief_title>
	<detailed_description>It find hemodialysis arteriovenous fistula failure partly mediate VEGF pathway . The administration bevacizumab ( VEGF-A monoclonal antibody ) arteriovenous fistula ( AVF ) murine model dose 5mg/kg ( standard chemotherapeutic dose ) show significant reduction stenosis formation overall improvement vascular remolding . However , previous pharmacokinetic human study show bevacizumab administer low dose 1.25mg intravitreally ( ocular neovascularization patient ) sufficient enough suppress circulate VEGF-A level 30 day post administration . A chart review 14 hemodialysis patient receive arteriovenous access intravitreal bevacizumab demonstrate significant improvement patency ( HR : 0.45 , p-value : 0.037 ) compare control . Prior phase 1 trial , essential determine intravenous administration bevacizumab demonstrate pharmacokinetics bio-response profile intravitreal administration , determine optimal dose frequency . This phase 0 study conduct 10 exist hemodialysis patient dose 1.25mg potential dose escalation 2.5mg optimal result see . The finding study substantial clinical impact ESRD patient also patient receive vascular endovascular procedure .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Inclusion Criteria Patients 18 85 year old , inclusive Patients end stage renal disease ( ESRD ) currently undergo hemodialysis treatment upper extremity fistula Hemoglobin ≥8g/dL platelet count ≥100,000/mm3 prior Day 1 Adequate liver function , define serum bilirubin ≤1.5 mg/dL ; gammaglutamyltransferase ( GGT ) , aspartate aminotransferase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase ≤2x upper limit normal international normalize ratio ( INR ) ≤ 1.5 prior Day 0 INR ≤ 2 anticoagulant therapy . Ability communicate meaningfully investigative staff , competence give write informed consent , ability comply entire study procedure If female childbearing year , must negative serum pregnancy test screen visit ( Visit 1 ) . Both female patient childbearing potential male patient childbearing potential partner must willing use contraception time screen completion study Life expectancy least 1 year Exclusion Criteria Known sensitivity bevacizumab prior treatment medication know target VEGF Current use medication know interact safety efficacy bevacizumab ( commonly : Antineoplastics ( Anthracyclines ) , Belimumab , Bisphosphonate Derivatives , Clozapine , Dipyrone , Irinotecan , Sorafenib , Sutent ) History evidence severe cardiac disease ( NYHA Functional Class III IV ) , myocardial infarction within six month study entry ( Day 1 ) , ventricular tachyarrhythmias require continue treatment , unstable angina Significant uncontrolled hypertension ( systolic blood pressure 160 mm Hg and/or diastolic blood pressure 100 mm Hg ) ; Stroke within six ( 6 ) month study entry ( Day 1 ) Treatment investigational drug/ device within 60 day prior study entry ( Day1 ) Treatment vitamin Kantagonists direct thrombin inhibitor INR ≥2 All patient ( include female patient childbearing potential male patient childbearing potential partner ) use highly effective method birth control ( failure rate le 1 % per year use consistently correctly ) , e.g . implant , injectables , combine oral contraceptive combination barrier method , intrauterine contraceptive device , sexual abstinence , vasectomized partner Malignancy treatment malignancy within previous 6 month Immunodeficiency include AIDS / HIV Active autoimmune disease Documented hypercoagulable state history 2 deep vein thromboses ( DVTs ) spontaneous intravascular thrombotic event Bleeding diathesis Anemia hematocrit level le 30 % A prothrombin time partial thromboplastin time 1.2 time upper limit normal , absolute platelet count low limit normal ; absolute neutrophil count 1,500/mm3 Active local systemic infection ( WBC &gt; 15,000/mm3 ) Gastrointestinal ulcer bleeding , wind dehiscence Scheduled elective surgery within 2 month start date Known serious allergy aspirin penicillin Any condition judgment investigator would preclude adequate evaluation safety efficacy bevacizumab Employees sponsor patient employee relative investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Arteriovenous Fistula</keyword>
	<keyword>Arteriovenous Graft</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>VEGF</keyword>
	<keyword>Avastin</keyword>
</DOC>